Effect of human recombinant Endostatin® protein on human angiogenesis

Angiogenesis

Volumn 5, Issue 1-2, 2002, Pages 111-118

  Jung, Sung P ^a,f   Siegrist, Brett ^a   Hornick, Conrad A ^b   Wang, Yi Zarn ^a   Wade, Mark R ^a   Anthony, Catherine T ^a   Woltering, Eugene A ^a,c,d,e  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f Soonchunhyang University   (South Korea)

Author keywords

Angiogenesis; Endostatin; Endothelium; Factor VIII; Neovascularization

Indexed keywords

ENDOSTATIN; HEPARIN; HYDROCORTISONE SODIUM PHOSPHATE; RECOMBINANT ENDOSTATIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; ENDOTHELIUM CELL; FIBRIN CLOT; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTITATIVE DIAGNOSIS; TUMOR GROWTH; VEIN BLOOD FLOW;

ANGIOGENESIS INHIBITORS; BIOLOGICAL ASSAY; COLLAGEN; COLLAGEN TYPE XVIII; ENDOSTATINS; HEPARIN; HUMANS; HYDROCORTISONE; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDE FRAGMENTS; PLACENTA; VEINS;

BOVINAE;

EID: 0036937605     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1021540328613     Document Type: Article

References (19)

1. Folkman J. Anti-angiogenesis: New concept for therapy of solid tumors. Ann Surg 1972; 175(3): 409-16.
2. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390(6658): 404-7.
3. Dhanabal M, Ramchandran R, Volk R et al. Endostatin: Yeast production, mutants, and anti-tumor effect in renal cell carcinoma. Cancer Res 1999; 59(9): 189-97.
4. O'Reilly MS, Boehm T, Shing Y et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88(2): 277-85.
5. Dhanabal M, Volk R, Ramchandran R et al. Cloning, expression, and in vitro activity of human endostatin. Biochem Biophys Res Commun 1999; 258(2): 345-52.
6. Dhanabal M, Ramchandran R, Waterman MJ et al. Endostatin induces endothelial cell apoptosis. J Biol Chem 1999; 274(17): 11721-6.
7. Kruger EA, Duray PH, Tsokos MG et al. Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay. Biochem Biophys Res Commun 2000; 268(l): 183-91.
8. Brown KJ, Maynes SF, Bezos A et al. A novel in vitro assay for human angiogenesis. Lab Invest 1996; 75(4): 539-55.
9. Meyers MO, Gagliardi AR, Flattmann GJ et al. Suramin analogs inhibit human angiogenesis in vitro. J Surg Res 2000; 91(2): 130-4.
10. Watson JC, Gebhardt BM, Alperin-Lea RC et al. Initiation of kdr gene transcription is associated with conversion of human vascular endothelium to an angiogenic phenotype. Surg Forum 1996; XLVII: 462-4.
11. Watson JC, Redmann JG, Meyers MO et al. Breast cancer increases initiation of angiogenesis without accelerating neovessel growth rate. Surgery 1997; 122(2): 508-14.
12. Jung SP, Siegrist B, Wade M et al. Inhibition of human angiogenesis with heparin and hydrocortisone. Angiogenesis 2001; 4(3): 175-86.
13. Hobson B, Denekamp J. Endothelial proliferation in tumors and normal tissues: Continuous labeling studies. Br J Cancer 1984; 49(4): 405-13.
14. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86(3): 353-64.
15. Hahnfeldt P, Panigrahy D, Folkman J, Hlatky L. Tumor development under angiogenic signaling: A dynamical theory of tumor growth, treatment response and postvascular dormancy. Cancer Res 1999; 59(19): 4770-5.
16. Rehn M and Pihlajaniemi T. Alpha 1 (XVIII), a collagen chain with frequent interruptions in the collagenous sequence, a distinct tissue distribution, and a homology with type XV collagen. Proc Natl Acad Sci USA 1994; 91(10): 4234-8.
17. Dixelius J, Larsson H, Sasaki T et al. Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood 2000; 95(11): 3403-11.
18. Sim BKL, Fogler WE, Zhou XH et al. Zinc ligand-disrupted recombinant human endostatin: Potent inhibition of tumor growth, safety and pharmacokinetic profile. Angiogenesis 1999; 3(1): 41-51.
19. Standker L, Schrader M, Kanse SM et al. Isolation and characterization of the circulating form of human endostatin. FEBS Lett 1997;420:129-33.